Paniccia R, Riccioni T, Zani B M, Zigrino P, Scotlandi K, Teti A
Department of Experimental Medicine, University of L'Aquila, Italy.
Endocrinology. 1995 Mar;136(3):1177-86. doi: 10.1210/endo.136.3.7867571.
Calcitonin (CT) is a peptide hormone that interacts with the cAMP-and phospholipase C-associated CT receptor subtypes. We investigated whether CT modulates the interaction of human tumoral osteoclast-like (GCT23) cells with a protein of the bone matrix, bone sialoprotein-II (BSP-II). Single GCT23 cells loaded with the intracellular Ca2+ indicator fura-2 were treated with the maximal active dose (300 micrograms/ml) of the 18-mer Arg-Gly-Asp (RGD)-containing BSP-IIA fragment, and the cytosolic free Ca2+ concentration ([Ca2+]i) was measured by dual wavelength microfluorometry. BSP-IIA stimulated an elevation in [Ca2+]i, consisting mainly of a peak, followed by a rapid return toward baseline. Pretreatment with CT induced a modest elevation of [Ca2+]i. However, CT significantly inhibited the response to BSP-IIA in a dose-dependent manner. Maximal inhibition (90% vs. untreated) was observed in the micromolar range. The intracellular mechanisms leading to this effect were investigated by pretreatment of GCT23 cells with the cAMP permeant analog, (Bu2)cAMP, and the protein kinase-C-activating agent, 12-O-tetradecanoylphorbol 13-acetate. Similar to CT, both agents inhibited the response to 300 micrograms/ml BSP-IIA. The effect induced by CT was specific, because an increase in the extracellular Ca2+ concentration, which is also known to inhibit bone resorption, failed to modify the ability of BSP-IIA to alter [Ca2+]i in GCT23 cells. To investigate whether the CT-induced alteration of BSP-IIA-dependent cell signals was due to a modification in the synthesis of cell surface receptors (integrins) for the extracellular matrix macromolecules, 1-h CT-treated [35S]methionine metabolically labeled GCT23 cell lysates were immunoprecipitated with anti-alpha 3-, -alpha v-, -beta 1-, and -beta 3-integrin subunit antibodies. Autoradiography demonstrated that 10(-7)-10(-6) M CT did not alter new synthesis of the alpha v beta 3 and the alpha 3 beta 1 receptors. Similarly, CT did not affect surface expression of these receptors, assessed by enzyme-linked immunosorbent assay. Finally, no alteration of the adhesion rate and spreading of GCT23 cells onto BSP-IIA-coated substrates was observed. This indicates that CT-induced down-regulation of immediate cell signals prompted by BSP-IIA in GCT23 cells is a postintegrin receptor event.
降钙素(CT)是一种肽类激素,可与环磷酸腺苷(cAMP)及磷脂酶C相关的CT受体亚型相互作用。我们研究了CT是否调节人肿瘤性破骨细胞样(GCT23)细胞与骨基质蛋白骨唾液酸蛋白-II(BSP-II)的相互作用。用细胞内Ca2+指示剂fura-2负载的单个GCT23细胞,用含18个氨基酸的精氨酸-甘氨酸-天冬氨酸(RGD)的BSP-IIA片段的最大活性剂量(300微克/毫升)处理,并用双波长显微荧光法测量胞质游离Ca2+浓度([Ca2+]i)。BSP-IIA刺激[Ca2+]i升高,主要表现为一个峰值,随后迅速恢复到基线水平。CT预处理可引起[Ca2+]i适度升高。然而,CT以剂量依赖的方式显著抑制对BSP-IIA的反应。在微摩尔范围内观察到最大抑制(与未处理相比为90%)。通过用cAMP渗透类似物(Bu2)cAMP和蛋白激酶C激活剂12-O-十四烷酰佛波醇13-乙酸酯预处理GCT23细胞,研究了导致这种效应的细胞内机制。与CT相似,这两种试剂均抑制对300微克/毫升BSP-IIA的反应。CT诱导的效应是特异性的,因为细胞外Ca2+浓度升高(已知也可抑制骨吸收)未能改变BSP-IIA改变GCT23细胞中[Ca2+]i的能力。为了研究CT诱导的BSP-IIA依赖性细胞信号改变是否是由于细胞表面受体(整合素)合成的改变,用抗α3、αv、β1和β3整合素亚基抗体对经1小时CT处理的[35S]甲硫氨酸代谢标记的GCT23细胞裂解物进行免疫沉淀。放射自显影显示,10(-7)-10(-6)M CT未改变αvβ3和α3β1受体的新合成。同样,通过酶联免疫吸附测定评估,CT不影响这些受体的表面表达。最后,未观察到GCT23细胞在BSP-IIA包被的底物上的黏附率和铺展的改变。这表明CT诱导的GCT23细胞中BSP-IIA引发的即时细胞信号下调是整合素受体后的事件。